Published • loading... • Updated
Breast Cancer in Metabolic Disorders: Experts Doubt the Enormous Benefit of GLP-1 RAs
Summary by Deutsches Ärzteblatt
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Richmond – Researchers from several institutions in the US state of Virginia claim to have demonstrated an extremely significant reduction in the mortality rate in patients with breast cancer and type 2 diabetes mellitus and/or obesity under therapy with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to other antidiabetic drugs...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
